| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/14/2005 | US6905832 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP) |
| 06/14/2005 | US6905692 Suitable for topical application to skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacteria, yeasts, fungi, viruses |
| 06/14/2005 | US6905685 Antiproliferative agents; monoclonal antibodies; blocking immunology response; autoimmune disease, antidiabetic agents, antiarthritic agents, antitumor, anticancer agents |
| 06/14/2005 | US6905677 Synergistic mixture of nucleoside and interferons |
| 06/14/2005 | US6905669 Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| 06/14/2005 | CA2400318C Botulinum toxin pharmaceutical compositions |
| 06/14/2005 | CA2333703C Isothiazole derivatives useful as anticancer agents |
| 06/14/2005 | CA2285463C A combination therapy for hiv infections |
| 06/11/2005 | CA2487578A1 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients |
| 06/09/2005 | WO2005052119A2 Adjuvants of immune response |
| 06/09/2005 | WO2005052005A1 Anti-igfr1 antibody therapeutic combinations |
| 06/09/2005 | WO2005051488A1 Combination of dopamine agonists and monoamine reuptake inhibitors |
| 06/09/2005 | WO2005051433A1 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
| 06/09/2005 | WO2005051426A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| 06/09/2005 | WO2005051425A1 Procaspase 1 activation inhibitor |
| 06/09/2005 | WO2005051413A2 Disease associated genes |
| 06/09/2005 | WO2005051389A1 Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| 06/09/2005 | WO2005051377A1 Use of schisandrin b for the manufacture of medicaments for treating diseases of tumors |
| 06/09/2005 | WO2005051367A1 Carboxamide and amino derivatives and methods of their use |
| 06/09/2005 | WO2005051365A1 Composition and device for facilitating venipuncture |
| 06/09/2005 | WO2005051361A1 Colonic purgative composition with soluble binding agent |
| 06/09/2005 | WO2005051331A2 Chaperone-based therapy for niemann-pick disease |
| 06/09/2005 | WO2005051321A2 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase |
| 06/09/2005 | WO2005051318A2 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| 06/09/2005 | WO2005051308A2 Methods of treating diseases and disorders by targeting multiple kinases |
| 06/09/2005 | WO2005051297A2 Combination drug therapy to treat obesity |
| 06/09/2005 | WO2005051104A1 Method for the preparation of multi-component mineral preparations |
| 06/09/2005 | WO2005037318A3 Treatment of arthritic conditions, chronic inflammation or pain |
| 06/09/2005 | WO2005025500A3 Process for preparing water soluble diterpenes and their applications |
| 06/09/2005 | WO2005021003A3 Immunosuppressive effects of pteridine derivatives |
| 06/09/2005 | WO2005011608A3 PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR |
| 06/09/2005 | WO2005009434A3 Compounds and methods for inducing apoptosis in cancer cells |
| 06/09/2005 | WO2005004906A3 Use of dp iv and apn inhibitors for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts |
| 06/09/2005 | WO2004096132A3 Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| 06/09/2005 | WO2004077938A3 Novel chemical entities and methods for their use in treatment of metabolic disorders |
| 06/09/2005 | WO2004071283A3 Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
| 06/09/2005 | WO2004062623A3 Method of treating functional bowel disorders |
| 06/09/2005 | WO2004041118A8 Therapeutic compositions for drug delivery to and through covering epithelia |
| 06/09/2005 | US20050125039 Treatment of hepatitis C using hyperthermia |
| 06/09/2005 | US20050124862 Thyroid hormone analogs and methods of use |
| 06/09/2005 | US20050124795 DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor |
| 06/09/2005 | US20050124791 Ion channel |
| 06/09/2005 | US20050124699 Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells |
| 06/09/2005 | US20050124697 Topical applying to skins; sunscreen agents; anticancer agents; using arylpropionic acid |
| 06/09/2005 | US20050124680 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment |
| 06/09/2005 | US20050124656 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) |
| 06/09/2005 | US20050124647 For example, 4-hydroxy-1,1-di-(5',6'-methylendioxy-indol-2-yl)-butane; antitumor agents, particularly for treating mammary carcinoma and colon carcinoma |
| 06/09/2005 | US20050124645 Methods and compositions for increasing CD4lymphocyte immune responsiveness |
| 06/09/2005 | US20050124633 For the treatment of myosin heavy chain-mediated diseases, and in particular, heart failure |
| 06/09/2005 | US20050124624 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases |
| 06/09/2005 | US20050124621 Novel inhibitors of kinases |
| 06/09/2005 | US20050124609 Orally administering to a patient a methylol transfer agent; e.g., an oral dose of about 100-1000 mg. of taurolidine, taurultam or mixtures; ulcerative colitis; Crohn's disease; reduces side effects when administered with other drugs; synergistic; bactericides; endotoxins; antiinflammatory agents |
| 06/09/2005 | US20050124592 Administering tibolone to female patients to treat estrogen-deficiency related, climacteric complaints exhibited while the female patients are being treated with a drug to prevent the biosynthesis of endogenous estrogen; aromatase inhibitors to prevent bone loss; reduced side efffcts for cancer patients |
| 06/09/2005 | US20050124591 Use of vitamin Ds to treat kidney disease |
| 06/09/2005 | US20050124589 New use, pharmaceutical preparations as well as a process for their production |
| 06/09/2005 | US20050124581 Alpha-substituted heteroarylalkyl phosphonate derivatives |
| 06/09/2005 | US20050124569 chemically synthesized double stranded siNA against Chemokine CXC Motif, Receptor 4 (CXCR4); modulate chemokine receptors such as CXCR4 and CXCR7A; use to inhibit viral infection (e.g., HIV), inflammatory diseases |
| 06/09/2005 | US20050124561 Administering fungicide for mucous membrane; asthma therapy |
| 06/09/2005 | US20050124558 Controlling particle size; bioavailability |
| 06/09/2005 | US20050124557 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 06/09/2005 | US20050124551 Or its cystine-coupled dimer, mixed with a nonsteroidal antiinflammatory agent used to treat contact dermatitis. |
| 06/09/2005 | US20050124549 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 06/09/2005 | US20050124543 Heterologous polypeptide of the TNF family |
| 06/09/2005 | US20050124537 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/09/2005 | US20050124536 Antifungal combination use |
| 06/09/2005 | US20050124534 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring |
| 06/09/2005 | US20050124533 Central nervous system disorders; adjust permeability of brain-bnlood barrier |
| 06/09/2005 | US20050124531 Angiogenesis inhibitors; prevent cancer cells metastasis; antiarthritic agents; skin disorders; retinopathy; atherosclerosis |
| 06/09/2005 | US20050124062 Culturing mammalian tissue in nutrient broth containing laminate biofilm comprising whey protein or beta -lactoglobulin and a plasticizer; for use in tissue engineering and regenerative medicine |
| 06/09/2005 | US20050124036 Method for producing recombinant proteins in micro-organisms |
| 06/09/2005 | US20050124004 Histamine receptor h3 polynucleotides |
| 06/09/2005 | US20050123999 Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods |
| 06/09/2005 | US20050123983 Methods and compositions for overcoming resistance to biologic and chemotherapy |
| 06/09/2005 | US20050123912 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders |
| 06/09/2005 | US20050123910 Nucleotide sequences coding prolyl oligopeptidase (DPP10) for use in identifying modulator which prevent and treat allergies, asthma, skin and inflammatory diseases |
| 06/09/2005 | US20050123909 Compositions and methods for treating cells having double minute dna |
| 06/09/2005 | US20050123897 Controlling flux of penetrants across adaptable, semipermeable porous barrier by enlarging applied dose per area; drug delivery kits, patches |
| 06/09/2005 | US20050123628 Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| 06/09/2005 | US20050123625 Compositions for treatment of viral-induced skin lesions and methods of using same |
| 06/09/2005 | US20050123610 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 06/09/2005 | US20050123609 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| 06/09/2005 | US20050123605 Anticancer agents; prevent forming blood vessels; removal blockage |
| 06/09/2005 | US20050123585 Two or more minerals: zinc, copper, manganese, tin or salt of zinc, copper, manganese for treating oral cavity plaque, oral cavity tartar, periodontal disease, gingivitis, breath odor of domestic animals |
| 06/09/2005 | US20050123577 Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs |
| 06/09/2005 | US20050123576 Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| 06/09/2005 | US20050123575 Heating, cooling, reheating and recooling a mixture containing hard fat while stirring; cosmetics, cosmeceutical, pharmaceutical; second temperature is lower than the congelation temperature of the mixture; hard fat is a mixture of triester of glycerin with caprylic, capric and stearic acids |
| 06/09/2005 | US20050123562 Novel composition |
| 06/09/2005 | US20050123551 Nucleic acids encoding polypeptides present in normal and neoplastic endometrial cells for use in diagnosis and treatment of endometrial cancer, identifying endometrial tissue; vectors, host cells; vaccines against endometrial cancer |
| 06/09/2005 | US20050123541 Anti-TNF antibodies, compositions, methods and uses |
| 06/09/2005 | US20050123531 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 06/09/2005 | US20050123523 Immunostimulatory nucleic acid molecules |
| 06/09/2005 | US20050123520 suspending tissue precursor cells in gels to form liquids, then filling the liquids into molds, implanting the mold into living host for incubation and demolding the tissues for use in surgery: tissue engineering |
| 06/09/2005 | US20050123512 Binding agents, vectors, host cells; gene therapy; nucleotide sequence with DNA insert encoding polypeptide; genetic engineering; medical diagnosis |
| 06/09/2005 | US20050123508 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders |
| 06/09/2005 | US20050123484 comprising a concentrate of a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon propellant, used for for accurate metered dose delivery |
| 06/09/2005 | US20050121024 Spray device |
| 06/09/2005 | DE10352131A1 Composition, useful to treat e.g. a morbid change to or an irritation of the prostate, comprises a first active agent (alpha antagonists or 5-alpha reductase inhibitors) and a second active agent (beta-3-adrenoceptor agonists) |
| 06/09/2005 | DE10351903A1 Neue Kombination New combination |
| 06/09/2005 | DE10347824A1 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut A pharmaceutical or cosmetic composition for treating the skin |
| 06/09/2005 | CA2814523A1 Colonic purgative composition with soluble binding agent |